175 related articles for article (PubMed ID: 36701413)
21. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study.
Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
Scand J Gastroenterol; 2021 Aug; 56(8):965-971. PubMed ID: 34165379
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma.
Chung JC; Oh MJ; Choi SH; Bae CD
ANZ J Surg; 2008 Apr; 78(4):245-51. PubMed ID: 18366394
[TBL] [Abstract][Full Text] [Related]
23. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
24. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
[TBL] [Abstract][Full Text] [Related]
25. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
26. "Depart from evil, and do good": Turning Axl from uncontrolled tumorigenic gene to biomarker for early detection of pancreatic cancer.
Comandatore A; Balsano R; Immordino B; Arguedas D; Capula M; Baglio SR; Garajovà I; Malapelle U; Morelli L; Giovannetti E
Crit Rev Oncol Hematol; 2022 May; 173():103659. PubMed ID: 35398264
[TBL] [Abstract][Full Text] [Related]
27. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
28. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
29. Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions.
Bararia A; Dey S; Gulati S; Ghatak S; Ghosh S; Banerjee S; Sikdar N
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):205-217. PubMed ID: 32312637
[TBL] [Abstract][Full Text] [Related]
30. [Pancreatic cancer-screening or surveillance?].
Sirtl S; Vornhülz M; Hofmann FO; Mayerle J; Beyer G
Radiologie (Heidelb); 2023 Dec; 63(12):908-915. PubMed ID: 37878016
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic profiling of pancreatic ductal adenocarcinoma plasma-derived small extracellular vesicles for cancer diagnosis and cancer stage prediction: a proof-of-concept study.
Zhang W; Wang L; Li D; Campbell DH; Walsh BJ; Packer NH; Dong Q; Wang E; Wang Y
Anal Methods; 2022 Jun; 14(23):2255-2265. PubMed ID: 35612592
[TBL] [Abstract][Full Text] [Related]
32. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
33. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
[TBL] [Abstract][Full Text] [Related]
34. Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma.
Chung HW; Lim JB; Jang S; Lee KJ; Park KH; Song SY
Cancer Sci; 2012 Sep; 103(9):1714-21. PubMed ID: 22703527
[TBL] [Abstract][Full Text] [Related]
35. Familial pancreatic cancer--status quo.
Fendrich V; Langer P; Bartsch DK
Int J Colorectal Dis; 2014 Feb; 29(2):139-45. PubMed ID: 23948969
[TBL] [Abstract][Full Text] [Related]
36. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
[TBL] [Abstract][Full Text] [Related]
37. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.
Zhou M; Diao Z; Yue X; Chen Y; Zhao H; Cheng L; Sun J
Oncotarget; 2016 Aug; 7(35):56383-56394. PubMed ID: 27487139
[TBL] [Abstract][Full Text] [Related]
38. Performance comparison between multi-center histopathology datasets of a weakly-supervised deep learning model for pancreatic ductal adenocarcinoma detection.
Carrillo-Perez F; Ortuno FM; Börjesson A; Rojas I; Herrera LJ
Cancer Imaging; 2023 Jun; 23(1):66. PubMed ID: 37365659
[TBL] [Abstract][Full Text] [Related]
39. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
40. Early Detection of Pancreatic Cancer: Opportunities and Challenges.
Singhi AD; Koay EJ; Chari ST; Maitra A
Gastroenterology; 2019 May; 156(7):2024-2040. PubMed ID: 30721664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
